Successful Treatment of Pure Red Cell Aplasia with High-Dose Dexamethasone after ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation
Publication date: Available online 18 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Rosario Varela Gomez, Goretti Vázquez Vazquez, Victor Noriega Concepcion, Andrea Galego Garcia, Concepción Andón Saavedra The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Dexamethasone | Hematology | Stem Cell Therapy | Stem Cells | Transplants